What risk level is Cannabidiol for workers compensation claims?

Cannabidiol is classified as Moderate risk (5 risk points) by AllMeds. Controlled cannabis medicine with significant CNS effects and workplace impairment risk.

What schedule is Cannabidiol in Australia?

Cannabidiol is classified as S8 under the Therapeutic Goods Administration (TGA) in Australia. Schedule 8 drugs are controlled substances with strict prescribing, dispensing, and monitoring requirements.

Can you work or drive while taking Cannabidiol?

Cannabidiol is a CNS depressant that may cause sedation, drowsiness, and impaired coordination. It can affect driving ability and work capacity, particularly in safety-sensitive roles. Work capacity should be assessed on a case-by-case basis.

What should a case manager know about Cannabidiol?

Case managers should note that Cannabidiol is Moderate risk. It is a CNS depressant that may affect work capacity. Recommended maximum duration is 90 days. It is reportable under SIRA guidelines in NSW. Always check for drug interactions with other medications on the claim.

Cannabinoid | Moderate Risk

Cannabidiol (Epidyolex)

What to know about Cannabidiol — also sold as Epidyolex: uses, side effects, interactions, and safety considerations for people taking it or caring for someone who is.

Cannabidiol (brand names: Epidyolex) is classified as Moderate risk (5 risk points) by AllMeds. It is a S8 medication under the TGA in Australia. Controlled cannabis medicine with significant CNS effects and workplace impairment risk.

Key Takeaways

TGA Schedule: S8 in Australia
Risk level: Moderate (5 points)
CNS depressant: May cause sedation, impair driving, and affect work capacity
Recommended maximum duration: 90 days
SIRA reportable: Flagged for NSW workers compensation reporting
PBS listed: Subsidised under the Australian Pharmaceutical Benefits Scheme

Scheduling and Classification

Jurisdiction	Classification	Status
Australia (TGA)	S8	PBS listed

Risk Profile

Risk Level Moderate

Risk Points 5

CNS Depressant Yes

Respiratory Risk No

Max Duration 90 days

Controlled cannabis medicine with significant CNS effects and workplace impairment risk.

How Cannabidiol is regulated

Cannabidiol is overseen by medicines regulators in each country. The rules below explain how it's scheduled, what oversight applies, and what to discuss with your doctor or pharmacist before starting, changing, or stopping this medication.

Work capacity impact: As a CNS depressant, Cannabidiol may impair driving, operating machinery, and cognitive function. Work capacity certificates should reflect any medication-related restrictions.

Australia TGA / PBS / State Schemes

Classified as S8 under the Therapeutic Goods Administration (TGA).

Listed on the Pharmaceutical Benefits Scheme (PBS) for subsidised prescribing.

Flagged as reportable under SIRA guidelines in NSW. Claims involving this medication may require additional reporting and clinical justification.

Check this medication against your full medication list

Run a full risk assessment including Cannabidiol interactions and compliance checks.

Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile in minutes. Free for individuals; team plans for case managers, insurers, and schemes.

Try it free → Talk to Sales →

Important: This page is general health information, not personal medical advice. If you have questions about your medication — including starting it, stopping it, changing the dose, or combining it with something else — speak with your doctor or pharmacist. For an emergency or suspected overdose, call your local emergency number or poison information service immediately. Information is drawn from regulator and clinical guideline sources (TGA, FDA, MHRA, NICE, PBS, CDC); see our methodology for details.